Pharmacokinetic drug interaction study: Administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine

American Journal of Therapeutics

Volumn 5, Issue 2, 1998, Pages 67-72

  Radwanski, Elaine ^a   Nomeir, Amin ^a   Cutler, David ^a   Affrime, Melton ^a   Lin, Chin Chung ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antacid; Bioavailability; Ceftibuten; H2 antagonist; Pharmacokinetic profile; Ranitidine

Indexed keywords

CEFTIBUTEN; MYLANTA; RANITIDINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG URINE LEVEL; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031924332     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199803000-00003     Document Type: Article

References (30)

1. Wiseman LR, Balfour JA: Ceftibuten: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994;47:784-808.
2. Jones RN: Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1995;14:S77-S83.
3. Neu HC: Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability. A rationale for dosing programs. Pediatr Infect Dis J 1995; 14:S88-S92.
4. Bauernfiend A: Ceftibuten and bacterial kinetics: comparative in vitro activity against Enterobacteriaceae producing extended-spectrum beta-lactamase. Diagn Microbiol Infect Dis 1990;14:89-92.
5. Wise R, Andrews JM, Ashby JP, et al: Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom. Diagn Microbiol Infect Dis 1991;14:45-52.
6. Verbist L, Jacobs J, Hens K: Comparative antimicrobial activity of ceftibuten against multiply-resistant organisms from Belgium. Drugs 1991;14:53-61.
7. Lode H, Fassbender M, Schaberg T, et al: Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994;47:S10-S20.
8. Barr WH, Affrime M, Lin CC, et al: Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995;14:S93-S101.
9. Barr WH, Lin CC, Radwanski E, et al: The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991;14:93-100.
10. Lin C, Lim J, Radwanski E, et al: Pharmacokinetics and dose proportionality of ceftibuten in men. Antimicrob Agents Chemother 1995;39:359-361.
11. Lin C, Radwanski E, Affrime M, et al: Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers. Antimicrob Agents Chemother 1995;39:356-358.
12. Harding S, Williams P, Ayrton J: Pharmacology of cefuroxime as the 1-acetonyethyl ester in volunteers. Antimicrob Agents Chemother 1984;25:78-82.
13. Brooks Gainer R II: Cefprozil, a new cephalosporin: its use in various clinical trials. South Med J 1995;88:338-346.
14. Roller S, Lode H, Stelzer I, et al: Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis 1992;11:851-856.
15. Bressolle F, Galtier M, Kinowski JM, et al: Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers. J Pharm Sci 1994;83:1236-1240.
16. Deppermann KM, Lode H, Hoffken G, et al: Influence of ranitidine, pirenzepine and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989;33:1901-1907.
17. Nakashima M, Uematsu T, Takiguchi Y, et al: Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. J Clin Pharmacol 1988;28: 246-252.
18. Wise R, Nye K, O'Neill P, et al: Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990;34:1053-1055.
19. Sadowski DC: Drug interactions with antacids: mechanisms and clinical significance. Drug Safety 1994;11:395-407.
20. Sommers DK, Van Wyk M, Moncrieff J, et al: Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol 1984;18:535-539.
21. Nix DE, Watson WAS, Lerner ME, et al: Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989; 46:700-705.
22. Grasela TH, Schentag JJ, Sedman AJ, et al: Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989;33:615-617.
23. Hooper DC, Wolfson JS: Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-394.
24. Hughes GS, Heald DL, Barker KB, et al: The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989;46:674-685.
25. 2 receptor antagonist. Antimicrob Agents Chemother 1992;36:796-800.
26. Nix DE, Wilton JH, Ronald B, et al: Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990;34:432-435.
27. Frost RW, Lasseter KC, Noe AJ, et al: Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992;36:830-832.
28. Healy DP, Sahai JV, Sterling LP, et al: Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. Antimicrob Agents Chemother 1989;33:1994-1997.
29. Blouin RA, Kneer J, Ambros RJ, et al: Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemother 1990;34: 1744-1748.
30. Shyu WC, Wilber RB, Pittman KA, et al: Effect of antacid on the bioavailability of cefprozil. Antimicrob Agents Chemother 1992;36:962-965.